NCT03511963已完成3 期
A Randomized, Double-blind, Parallel Control, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of HLX04 and Bevacizumab Combined With Oxaliplatin and Fluoropyrimidine-based Chemotherapy (XELOX or mFOLFOX6) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Shanghai Henlius Biotech1 个研究点 分布在 1 个国家目标入组 677 人开始时间: 2018年4月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 677
- 试验地点
- 1
- 主要终点
- PFSR9m
研究概览
简要总结
This trial is conducted in patients with the recurrent lesion(s) post-surgery or the untreated mCRC. After stratification with respect to ECOG PS score, chemo regimen, primary tumor location and KRAS and BRAF genotype (complete wild-type/primal type), eligible patients are randomized into two arms at 1:1 ratio to receive HLX04 (Arm A) or Bevacizumab (Arm B) in combination with one of the protocol-defined chemotherapies, modified FOLFOX6 (mFOLFOX6) or XELOX for mCRC until disease progression (PD) or unacceptable toxicity or achieving an operable contingency, whichever occurs first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Life expectancy ≥ 6 months
- •Histologically confirmed colorectal cancer with a metastatic / recurrent lesion that cannot be cured by surgery.
- •At least one measurable lesion have been the confirmatory detection within 4 weeks prior to the randomization with respect to RECIST 1.1
- •No prior first-line systemic anti-tumor therapy for mCRC (including systemic chemotherapy, molecular targeted therapy, biotherapy, and other study treatment) have been identified
- •At least 6 months have elapsed if considering the interval from the time of firstly documented metastasis to the post-operational adjuvant chemotherapy termination
- •Adequate organ function as indicated by the following laboratory values:
- •Absolute neutrophil count (ANC) ≥1,500 /mm3（1.5×109 /L）
- •Platelets ≥80,000 / mm3（80×109 /L）
- •Hemoglobin ≥9 g/dL, within the 2 weeks prior to the screening no need for the transfusion
- •Serum creatinine ≤1.5 X upper limit of the normal (ULN) or creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula
- •Serum total bilirubin ≤ 1.5 X ULN
- •AST (SGOT), ALT (SGPT) and alkaline phosphatase (ALK) ≤ 3 X ULN (AST/ALT ≤ 5 X ULN if liver metastatic; ALK ≤ 5 × ULN if liver and/or bone metastastic)
- •International Normalized Ratio (INR) or Prothrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN; ( if patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intent using goal of anticoagulants)
- •The subjects are accredited with good compliance, signed the informed consent, and capable to cooperate, completing the relevant examination and follow-ups.
排除标准
- •Targeted medicine(including Bevacizumab, cetuximab, panedol, arbicip, rigofeni, etc) was used before as adjuvant therapy.
- •Cerebral and/or leptomeningeal metastasis.
- •Bleeding predisposition, high bleeding risk or coagulant disorder, thrombotic event(s) occurrence ≤6 months and/or hemoptysis ≤3 months (≥ 1/2 teaspoons fresh blood each) prior to the screening; use of full dose oral or parenteral anticoagulant or thrombolytic medication (allowing preventative anticoagulation); use of aspirin (> 325 mg/day) or other platelet-inhibition non-steroidal anti-inflammatory drugs within 10 days since the screening; CT/MRI imaging evidence, testimony of the main arteries/veins (such as pulmonary artery or superior vena cava) being infringed, encroached.
- •Subjects with uncontrolled hypertension and with a medical history of hypertensive crisis or hypertensive encephalopathy; serious cardiovascular and cerebrovascular diseases, including cerebrovascular accident (CVA) ≤6 months before the screening, transient ischemic attack (TIA), myocardial infarction and significant vascular disease (including but not limited to aortic aneurysms with need for surgical repair or recent evidence of arterial thrombosis), unstable angina, heart failure and serious arrhythmias that are uncontrolled by drugs (New York Heart Association Class ≥2).
- •Subjects with non-healing wounds, active peptic ulcer or fracture and active infection; tracheal esophageal fistula, gastrointestinal perforation or gastrointestinal fistula and abdominal abscess in the 6 months prior to the screening;Uncontrolled infection,including HIV,HBV,HCV and syphilis .
- •Subjects allergic to bevacizumab, oxaliplatin, 5-FU/capecitabine or folinic acid injection and the relevant ingredients and excipients.
- •Pregnant women and lactating women; women of potential childbearing age and male subjects do not use effective contraception during the study period, and during the 6 months after the last study drug administration effective contraception cannot be assured.
- •Presence of other active malignancies or a history of other malignancies within the past 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.
- •Subject is currently enrolled in, or ≤4 weeks since subject participating another investigational device or drug study(s), or subject is receiving other investigational agent(s).
- •Any other medical condition that renders disqualification for the inclusion in the study according to the investigator discretionary judgment.
研究组 & 干预措施
HLX04
Experimental
干预措施: HLX04 100 mg in 4 ml Injection (Drug)
Bevacizumab
Active Comparator
干预措施: Avastin 100 mg in 4 ml Injection (Drug)
结局指标
主要结局
PFSR9m
时间窗: 0 to 36 weeks
Progression free survival rate (PFS rate) at Month 9 (PFSR9m)
次要结局
- BORR(0 to 48 weeks)
- ORR(6 to 48 weeks)
- DOR(0-48 weeks)
- SAE(0-48 weeks)
- OSR(0 to 48 weeks)
- TTR(0-48 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.Myasthenia Gravis GeneralisedNCT00408213Hoffmann-La Roche136
招募中
不适用
Hip Arthroscopy Postoperative Opioid DemandsOpioid UsePainFemoral Acetabular ImpingementLabral Tear, GlenoidNCT04094701Rush University Medical Center170
已完成
1 期
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus InfectionOral Herpes SimplexNCT01308424Beech Tree Labs, Inc.171
已完成
3 期
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01007435Hoffmann-La Roche1,162
进行中（未招募）
3 期
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaMelanoma (Skin)NCT05986331Biocad366